Navigation Links
Experts to Provide Successful Strategies for Global Biopharmaceutical Development and Commercialization at PAREXEL Tokyo Seminar

BOSTON, Sept. 28, 2011 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that it will hold its annual seminar for biopharmaceutical companies and multinational affiliates based in Japan and throughout Asia on October 5, 2011 at the Grand Hyatt Tokyo in Japan. The seminar will focus on successful strategies for global drug development, as well as the implementation of development plans to achieve maximum quality, speed and commercial uptake. Experts will provide best practices to achieve seamless development of a molecule from early phase research to commercialization.

Attendees will learn how to benefit from strategic partnerships, which have emerged as essential mechanisms for meeting the biopharmaceutical industry's needs for improved efficiency and effectiveness. Presenters will address how partnerships can enable biopharmaceutical companies headquartered in Japan and throughout the Asia/Pacific region to access world-class talent and best-practice processes to support the acceleration of global development programs.

The seminar's opening remarks will be presented by Yasuharu Orihara, General Manager, Japan, PAREXEL and Albert Liou, Vice Chairman, Asia/Pacific Region, PAREXEL.  The event will include the following featured presentations:

  • Professor Yuji Sato, M.D., Ph.D., Director, Centre for Clinical Research, Keio University School of Medicine will present "Issues and Challenges in Japanese Research"
  • PAREXEL Chairman and Chief Executive Officer Josef von Rickenbach will provide the keynote address "The Current Status of Outsourcing in Japan and Globally"
  • Alberto Grignolo, Ph.D., Corporate Vice President, PAREXEL will address "Developing a New Drug:  Planning for Maximum Market Access"

  • For more information about this seminar visit:  Seminar registration for biopharmaceutical companies and media can be found at:

    About PAREXEL InternationalPAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement.  Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process.  Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has approximately 10,550 employees. For more information about PAREXEL International visit

    This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.  For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should,"  "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated restructuring charge of approximately $18 million over the fourth quarter of Fiscal Year 2011 as well as the first and second quarters of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.   Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2011 as filed with the SEC on August 26, 2011, which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

    PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.Contacts:Jennifer Baird, Senior Director of Public Relations

    Kim Baker/Gene CarozzaPAREXEL International

    PAN CommunicationsTel: +781-434-4409

    Tel: + 617-502-4300Email:


    SOURCE PAREXEL International Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. European Experts Recommend Pregnant and Nursing Women Take More DHA - Every Day
    2. Seriously Low Vaccination Rates Cause Experts to Call for Increased Immunization Before Influenza Season Peaks
    3. Experts Call for Widespread Use of Memory Screenings and Emphasize Value of Early Detection of Dementia
    4. Health Experts and Families Encourage Annual Childhood Flu Vaccination to Reduce Flu-Related Illnesses and Deaths in Children
    5. Vical Receives NIH Grant for an Immunotherapeutic Herpes DNA Vaccine; Herpes Experts at University of Washington and University of Texas to Conduct Preclinical Development
    6. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
    7. Heart Patients More Likely to Adopt Healthy Habits in 3-Year Program Led by Cardiac Rehabilitation Experts, Mayo Clinic Research Shows
    8. Promise of Vicals CMV Vaccine Noted by Independent Experts
    9. Kendle Experts to Present at the Drug Information Association 44th Annual Meeting
    10. Cytels Clinical Innovation Experts Cyrus Mehta and Judith Quinlan Reveal Latest Adaptive Trial Successes at 44th Annual DIA Meeting
    11. Despite Advances in the Accuracy of CT Colonography in Detecting Polyps, Digestive Health Experts Urge Patients to Consider Risks and Realities
    Post Your Comments:
    (Date:11/30/2015)... , Nov. 30, 2015   Royal Philips ... Implant, the industry,s first MRI guided user interface and ... of patients with MR Conditional implants, such as knee ... 2015 Radiological Society of North America Annual Meeting ... and supports diagnostic confidence of this growing patient population. ...
    (Date:11/30/2015)... BOCA RATON, Fla. , Nov. 30, ... of Public Research (the Institute) announced today that ... , a medical device start-up company with technology developed ... creation based on publicly-funded research, and bridges early funding ... -based universities and research institutions. ...
    (Date:11/30/2015)... Nov. 30, 2015 Baxalta Incorporated ... leader dedicated to delivering transformative therapies to ... conditions, today announced the launch and first ... an extended circulating half-life recombinant factor VIII ... full-length ADVATE [Antihemophilic Factor (Recombinant)]. The treatment ...
    Breaking Medicine Technology:
    (Date:11/30/2015)... ... November 30, 2015 , ... ... last 15 years, announced today that Michigan-based Family Health Center (FHC) has selected ... over 45 years, FHC was awarded the largest Affordable Care Act grant for ...
    (Date:11/30/2015)... Ill. (PRWEB) , ... November 30, 2015 , ... ... Decision Support Solutions, announced at the Radiology Society of North America (RSNA) annual ... have seen over 60% growth from 2014. Throughout 2015, the company has ...
    (Date:11/30/2015)... , ... November 30, 2015 , ... ... publishing magazines and websites specializing in independent living, assisted living and all other ... and Alzheimer’s awareness and research remains a top priority. , ...
    (Date:11/30/2015)... , ... November 30, 2015 ... ... is pleased to announce the speakers for “Value-Based Payer-Provider Partnerships: Three Case ... from three innovative value-based care arrangements: Essentia Health and UCare, MissionPoint Health ...
    (Date:11/30/2015)... PA (PRWEB) , ... November 30, 2015 , ... ... software provider, has verified that their Vasont Universal Integrator (VUI) extension unites with ... creating, editing, and managing content as a continuous process with the latest release ...
    Breaking Medicine News(10 mins):